The FDA just approved the first generic version of Climara Pro, a once-weekly transdermal hormone therapy patch made by Zydus Pharmaceuticals. The patch delivers estradiol and levonorgestrel to treat moderate-to-severe menopausal symptoms and prevent postmenopausal osteoporosis in women with an intact uterus. Experts say the generic option could make this convenient, effective therapy more accessible and affordable for more women.
The FDA has given the green light to the first generic version of Climara Pro, a once-weekly transdermal hormone therapy (HT) patch manufactured by Zydus Pharmaceuticals. The patch is therapeutically equivalent to the brand-name Climara Pro (Bayer) and is approved for women with an intact uterus who need relief from moderate-to-severe vasomotor symptoms (think hot flashes) and protection against postmenopausal osteoporosis.
The patch delivers a combination of estradiol (0.045 mg/day) and levonorgestrel (0.015 mg), with the progestogen component included specifically to reduce the risk of endometrial hyperplasia. Experts highlight that transdermal estradiol is a preferred delivery method because it bypasses the liver, potentially lowering the risk of blood clots compared to oral estrogens.
Key Takeaways:
Why it matters: Hormone therapy remains one of the most effective tools for managing menopause symptoms, but cost and complexity can be barriers. A more affordable, easy-to-use generic option could meaningfully improve treatment adherence and access for women who need it most.
